Antiviral Drug Remdesivir By Gilead:Most Effective For Treating 2019-nCoV Coronavirus According To Study Trials Published Last Week In NEJM Journal
Already at the start of the coronavirus
outbreak in late December 2019, Chinese medical researchers and doctors were already treating coronavirus
infected patients with a HIV antivira
l called Aluvia
, also known as Kaletra
, which is is a combination of lopinavir
and is produced by pharmaceutical company AbbVie. (simply goggle online and you can see that many medical sites were already talking about the usage of this drug for coronavirus since early January 2020.)
s were the first choice as there was already more than 37 previous published clinical studies that showed it was effective for the SARS coronavirus
and since the 2019-nCoV coronavirus
was similar to the SARS coronavirus
(initial gene sequencing had shown a 84 to 87 percent match), it was the first choice.
The Chinese doctors also experimented with other combo protocols using the HIV antivirals
along with influenza antivirals
such as oseltamivir phosphate (available as a generic version or under the trade name Tamiflu®), zanamivir (trade name Relenza®), peramivir (trade name Rapivab®) and.baloxavir marboxil (trade name Xofluza®).
However the Chinese doctors found that the drug combinations were not effective especially in patients in serious stages as it aggravated their kidney functions and lead to kidney failure and even accelerated the organ failure conditions they were already experiencing in the latent stages of the disease.
Later an adopted protocol was to take two standard doses of lopinavir
along with a dose of nebulized alpha-interferon
twice a day. Using this protocol, more than 230 patients were cured according to Guizhou Medical University in China.
Pharma had another more effective antiviral
drug candidate called remdesivir
which is actually a nucleotide analog prodrug. The company shipped stocks to the Chinese as early as mid-January 2020 for testing.
also started laboratory testing of remdesivir
against 2019-nCoV. In those studies, Gilead
stated that remdesivir was also "shown to be active" against SARS and MERS in animals.
The drug was administered to the first US patient confirmed with the 2019-nCoV coronavirus
since the 22nd of January for "compassionate use" after he progressed to pneumonia.(this was done with USFDA and CDC support and approvals)
The patient has since recovered and the findings of that drug trial have been published in The New England Journal of Medicine since the 31st
of January 2020.
Meanwhile since the late January 2020, Chinese medical researchers stated to the media that in exploratory research considering a selection of 30
drug candidates, three of them, remdesivir, chloroquine and lopinavir
, seemed to have "fairly good inhibitory. effects" on 2019-nCoV at the cellular level. Requests to start clinical testing were submitted along with that for remdesivir.
The American trial and also subsequent Chinese trials all indicate that it is the current drug choice for treatment. Gilead
is planning further trial and also to get the drug repurposed for 2019n-CoV treatment with the US FDA.
The public is to be aware and there are some South-east Asian entities claiming to have invented the cure for the 2019-nCoV or have invented these drugs and these protocols and some of this claims have been published in unreliable media with journalist that are totally ignorant of medical matters. The same also goes about allegations of certain doctors in South-east Asia who had discovered the MERs virus first, this is not true and the same goes about them discovering the new coronavirus before the Chinese or others, even in terms of genomic mapping.)
For more reliable updates about the China coronavirus epidemic or the Thailand Coronavirus scenario, keep on checking at: https://www.thailandmedical.news/articles/coronavirus